Skip to main content
S&P 5007,568.92+0.36%DOW51,786.72-0.38%NASDAQ25,372.01+0.83%BTC$76,850.00-0.36%ETH$2,261.28+0.13%GOLD$3,968.20+0.71%OIL$95.60-0.51%
Smart Investors Daily
SID Premium
CD

NASDAQ · CDNA

CareDx, Inc

Healthcare · Medical - Diagnostics & Research

$88.47

Up+$2.59 (+3.02%)

Updated Nov 4, 2026, 5:14 AM

SID Score

6.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.02B
P/E ratio
17.11
Dividend yield
0.00%
52-week range
$15.56 – $90.87
Volume
1.59M
Avg. volume
1.12M

Price performance · CDNA

CDNA price history

1M range · 0 trading sessions · Daily adjusted prices

CDNA does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest CDNA news

The latest Smart Investors Daily articles mentioning CDNA.

Stock researchCompany · Overview

CDNA research

Overview

Company profile and research snapshot.

Company profile

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$28.80
Implied upside
—
Analysts
15
CDNA recent ratings
DateFirmRatingTarget
Oct 30, 2026BTIGBuy—
Oct 27, 2026BTIGBuy—
Oct 19, 2026Canaccord GenuityBuy—
Sep 24, 2026BTIGBuy—
Sep 2, 2026Canaccord GenuityBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 27, 2026

CareDx (CDNA) After Kidney Week Data Is The Story Already Priced In

How the Kidney Week data event ties to the CareDx investment story CareDx (CDNA) used the American Society of Nephrology Kidney Week 2026 to spotlight fresh data on its AlloSure Kidney test, tying the product more tightly to real world transplant decision making. The new analyses focus on donor derived cell free DNA as a signal for graft injury, especially in situations where biopsies give borderline or ambiguous results that leave clinicians uncertain about next steps. For investors tracking...

Yahoo · Oct 22, 2026

CareDx Announces New KOAR Data Linking Elevated AlloSure® Kidney to Nearly 3-Fold Higher Risk of Adverse Graft Outcomes in Patients with Borderline Rejection or TCMR at ASN Kidney Week 2026

BRISBANE, Calif., October 22, 2026--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today highlighted data featuring AlloSure® Kidney donor-derived cell-free DNA (dd-cfDNA) being presented at the American Society of Nephrology (ASN) Kidney Week 2026, taking place October 22–25 in Denver, Colorado.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By